ストックスクリーナーアプリを入手
0.4652
2.27%
-0.0108
アフターアワーズ：
.50
0.0348
+7.48%
前日終値:
$0.476
開ける：
$0.48
24時間の取引高:
821.67K
Relative Volume:
5.20
時価総額：
$16.79M
収益：
-
当期純損益:
$-10.21M
株価収益率:
-0.7963
EPS:
-0.5842
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-22.74%
1か月 パフォーマンス:
-35.39%
6か月 パフォーマンス:
-49.43%
1年 パフォーマンス:
-74.16%
1日の値動き範囲:
$0.4322
$0.4999
1週間の範囲:
$0.4322
$0.6349
52週間の値動き範囲:
$0.4322
$1.98
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Compare NRSN vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.4652 | 21.19M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Neurosense Therapeutics Ltd (NRSN) 最新ニュース
Neurosense Therapeutics is a buy, this analyst says - Cantech Letter
Neurosense Therapeutics Ltd expected to post breakeven results a shareEarnings Preview - TradingView
Neurosense Therapeutics Ltd. Revenue Breakdown – FWB:H1Z - TradingView
Neurosense Therapeutics Ltd - TradingKey
Neurosense Therapeutics Ltd (NRSN) Cash Flow - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.602|Chg%:-0.048 - TradingKey
Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS - TipRanks
NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug - Stock Titan
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PR Newswire
NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66Calendar Spread Trade - dars.gov.et
NeuroSense Therapeutics (NRSN) Edges Higher as Key Support HoldsEquity Put Call - dars.gov.et
NeuroSense Therapeutics Ltd. (NRSN) Latest Stock News & Headlines - Yahoo Finance
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - Nasdaq
Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
NeuroSense Therapeutics Ltd. Warrant 2021-open end Financial Disclosures & SEC Filings - TradingView
NeuroSense bolsters case for multi-target Alzheimer’s strategy - Longevity.Technology
NRSN Q2 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Revision Upgrade - dars.gov.et
NeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALS - Bakersfield.com
NeuroSense (NRSN) Achieves Key Milestone in ALS Study - GuruFocus
NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3 - TipRanks
NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint - marketscreener.com
NeuroSense (NRSN) Phase 2b ALS study cuts TDP-43, eyes Phase 3 - Stock Titan
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - Nasdaq
NeuroSense reports positive Phase 2b ALS data - grafa.com
NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer’s disease - BioSpectrum Asia
Neurosense Therapeutics Ltd. Actuals & Estimates (NASDAQ:NRSN) - TradingView
Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
NRSN Forecast — Price Target — Prediction for 2027 - TradingView
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD - GuruFocus
Price to book forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Number of shareholders of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial - TipRanks
NeuroSense (NRSN) reports early Phase 2 PrimeC biomarker signals in Alzheimer’s - Stock Titan
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease - PR Newswire
Enterprise value to EBITDA forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Number of shareholders of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Price to sales forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Enterprise value to EBIT forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
EverythingALS to Host NeuroSense in a Community Event Named: PrimeCConnecting the Dots - The AI Journal
EverythingALS to Host NeuroSense in a Community Event Named: Pri - GuruFocus
ALS community event puts NeuroSense’s PrimeC data in focus June 24 - Stock Titan
NRSN Q2 2025 Earnings: Narrower Loss Per Share Beats Estimates, Stock SurgesBuyback Announcement Report - po-news-eg.net
NRSN Q1'26 Earnings: EPS estimate is (0.08) USD - TradingView
Neurosense Therapeutics Ltd (NRSN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurosense Therapeutics Ltd (NRSN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Institutional Confidence - TradingKey
Neurosense Therapeutics Ltd (NRSN) 財務データ
収益
当期純利益
現金流量
EPS
Neurosense Therapeutics Ltd (NRSN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ben-Noon Alon | Chief Executive Officer |
Jun 16 '26 |
Buy |
0.80 |
250,000 |
200,000 |
4,534,233 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):